Use our chat feature to speak with one of our expert consultants who can help you identify if medical cannabis can help you.
6 min read
Research Report URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339496/
Because we are passionate about making medical cannabis knowledge accessible, we break down some of the latest and greatest medical cannabis research reports and scientific investigations into bite-sized chunks.
Here we provide summarised findings of the evidence that was discovered and discussed in the 2023 paper ‘A comparison of advertised versus actual cannabidiol (CBD) content of oils, aqueous tinctures, e-liquids and drinks purchased in the UK’.
This study aims to address concerns about the quality of CBD products and the discrepancies between advertised and actual CBD concentrations. By comparing the advertised CBD content in oils, aqueous tinctures, e-liquids and drinks sold in the UK with their actual cannabidiol contents, this paper reveals how much these figures deviate and emphasise the importance of maintaining standard operating procedures.
This paper contributes evidence that shows how inaccurate the advertising of certain CBD products can be in the UK. It assesses the CBD concentrations in a broader range of products than has previously been examined within the UK, and aims to address concerns about the quality of CBD products and the discrepancies between advertised and actual CBD concentrations.
There are a number of practical implications discussed in this paper, including:
The over-labelling of CBD concentrations within UK products highlights the need for improved product standards, which may necessitate clearer legislative guidance on the acceptable tolerance limits for advertised CBD concentrations.
The study found that the magnitude of deviation from advertised CBD concentrations differed between product types was not related to product price, and BD-oils deviated less from their advertised concentrations than aqueous tinctures, e-liquids, and drinks.
The findings suggest that consumers should be cautious when purchasing CBD products and should look for products that have been independently tested for CBD content.
The introduction of this paper provides an overview of the growing consumer demand for CBD-containing products, which are now available in various forms, including oils, aqueous tinctures, e-liquids, drinks, edibles, and topical creams/gels. However, concerns have been raised regarding the quality of these products, with discrepancies between advertised and actual CBD content, and contamination with other, illicit cannabinoids.
The paper aims to address these concerns by assessing CBD concentrations in a broader range of products than has previously been examined within the UK, including oil-and aqueous-based tinctures, e-liquids, and drinks.
The paper provides a literature survey of previous studies that have examined the quality of CBD-containing products. The authors note that previous studies have found discrepancies between advertised and actual CBD content, with some products containing little to no CBD, while others contain higher levels of CBD than advertised. Additionally, some products have been found to be contaminated with other cannabinoids, such as THC, which can have psychoactive effects.
The authors also note that there is limited information on how different types of CBD products may differ in their deviation from advertised CBD concentrations. Therefore, the current study aims to address this gap in the literature by quantifying and comparing CBD concentrations in different types of products.
The authors used high-performance liquid chromatography (HPLC) with a Raptor ARC-18 LC reverse phase column and ultraviolet detection to quantify CBD and cannabidiolic acid (CBDA) concentrations in aqueous tinctures, oils, e-liquids, and drinks. Reported CBD concentrations using HPLC reflect the combination of measured CBD and theoretic conversion of CBDA to CBD.
The authors also compared the advertised CBD concentrations to the actual CBD concentrations in each product and analysed the data to determine if there was a relationship between product type, price, and deviation from advertised CBD concentration.
The paper concludes that there is a need for improved product standards and clearer legislative guidance on acceptable tolerance limits for advertised CBD concentrations due to the over-labelling of CBD concentrations within UK products.
The magnitude of deviation from advertised CBD concentrations differed between product types but was not related to product price, with CBD-oils deviating less than aqueous tinctures, e-liquids, and drinks.
In this area, future research may seek to determine rates of CBD degradation in consumer products, and within-product variability in labelling accuracy. Furthermore, CBD used in research investigating its psychological or physiological effects should be analysed to confirm that CBD concentrations are appropriate.
The limitations of this paper include:
Future research suggested in this paper includes:
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
Get comprehensive care, convenience, and confidence with an all-in-one treatment plan.
Am I eligible?All of our articles are written by medical cannabis experts, guided by strict sourcing guidelines, and reference peer-reviewed studies and credible academic research. Our expert clinical team and compliance specialists provide valuable insights to ensure accuracy when required. Learn more in our editorial policy.
Need more help?
For some patients, medical cannabis really is a lifeline and is therefore a necessary component in the holiday of a lifetime. So that you don’t have to choose between your health and a holiday, we’ve put together this guide that explains which countries currently have medical cannabis policies in place.
Lucy MacKinnon
Here at Releaf we understand that holidays should be about relaxation, but travelling with medical cannabis sounds like a stressful voyage. We’re doing what we can to absorb that stress so that you can soak up the sun, and so, we’ve designed a series of articles to cover the subject: medical cannabis on holiday.
Lucy MacKinnon
The time it takes for you to feel the effects of THC depends on the methods of administration as well as your own physiology. Fortunately, there are fast and slow-acting options, as well as ways to take low or high doses in order to facilitate control over the way your body reacts to your medicine.
Editorial Team
